Heavy Metal Neuropathies

  • Karen S. Blisard


CASES OF HEAVY METAL POISONING, although uncommon, do occur in ordinary clinical practice. The manifestations can be subtle or devastating, depending on the exposure, and the diagnosis can be difficult.


Dorsal Root Ganglion Schwann Cell Methyl Mercury Myelin Sheath Axonal Degeneration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klaassen CD, Amdur MO, Doull J: Casaren and Doull’s Toxicology: the Basic Science of Poisons, 3rd Ed. Macmillan, New York, 1986.Google Scholar
  2. 2.
    Dyck PJ, Thomas PK, Lambert EH, et al.: Peripheral Neuropathy, 2nd Ed. W.B. Saunders, Philadelphia, 1984.Google Scholar
  3. 3.
    Adams JH, Corsellis JAN, Duchen LW: Greenfield’s Neuropathology, 4th Ed. Wiley Medical, New York, 1984.Google Scholar
  4. 4.
    Schochet SS (ed): Neuropathology. The Clinical Neurosciences, vol. 3. Churchill Livingstone, New York, 1983.Google Scholar
  5. 5.
    Vinken PJ, Bruyn GW (eds): Intoxications of the Nervous System, Pt. 1, Handbook of Clinical Neurology, vol. 36, North-Holland Biomedical Press, Amsterdam, 1979.Google Scholar
  6. 6.
    Luna LG (ed): Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, 3rd Ed. McGraw-Hill, New York, 1968.Google Scholar
  7. 7.
    Sheehan DC, Hrapchak BB: Theory and Practice of Histotechnology, 2nd. Ed. C.V. Mosby, St. Louis, 1980.Google Scholar
  8. 8.
    Elftman H, Elftman AG: Histological methods for the demonstration of gold in tissues. Stain Technol 20:59–62, 1945.Google Scholar
  9. 9.
    Elftman H, Elftman AG, Zwemer RL: Histochemical distribution of gold after administration of gold chloride. Anat Record 96:341–353, 1946.Google Scholar
  10. 11.
    Gilg G, Vraa-Jensen G: Histological examination of the central nervous system after gold treatment. Acta Psych Neurol Scand 33:174–180, 1958.Google Scholar
  11. 12.
    Danscher G: Localization of gold in biological tissue. Histochem 71:81–88, 1981.Google Scholar
  12. 13.
    Schochet SS: Diagnostic Pathology of Skeletal Muscle and Nerve. Appleton-Century-Crofts, Norwalk, CT, 1986.Google Scholar
  13. 14.
    Landon DN: Structure of normal peripheral myelinated nerve fibres, in Waxman SG, Ritchie JM (eds.): Demyelinating Disease: Basic and Clinical Electrophysiology, Adv Neurol 31:25–49, 1981.Google Scholar
  14. 15.
    Cavanagh JB: The significance of the ‘dying back’ process in experimental and human neurological disease. Internati Rev Exp Pathol 3:219–267, 1964.Google Scholar
  15. 16.
    Schoental R, Cavanagh JB: Mechanisms involved in the ‘dying-back’ process-an hypothesis implicating coenzymes. Neuropathol App Neurobiol 3:145–157, 1977.Google Scholar
  16. 17.
    Cavanagh JB: The ‘dying back’ process: a common denominator in many naturally occurring and toxic neuropathies. Arch Pathol Lab Med 103:659–664, 1979.PubMedGoogle Scholar
  17. 18.
    Spencer PS, Schaumburg HH: Central-peripheral distal axonopathy-the pathology of dying-back polyneuropathies, in Zimmerman HM (ed): Progress in Neuropathology, vol. III, New York, Grune & Stratton, 1976, pp. 253–295.Google Scholar
  18. 19.
    Spencer PS, Schaumburg HH: Classification of neurotoxic disease: a morphological approach. Experimental and Clinical Neurotoxicology. Williams and Wilkins, Baltimore, 1980, pp. 92–99.Google Scholar
  19. 20.
    Jakobsen J, Sidenius P, Braendgaard H: A proposal for a classification of neuropathies according to their axonal transport abnormalities. J Neurol Neurosurg Psych 49:986–990, 1986.Google Scholar
  20. 21.
    Jacobs JM: Vascular permeability and neural injury. In: Experimental and Clinical Neurotoxicology. Spencer PS, Schaumburg HH (eds): Williams and Wilkins, Baltimore, 1980, pp. 102–117.Google Scholar
  21. 22.
    Tsalev DL, Zaprianov ZK: Atomic Absorption Spectrometry in Occupational and Environmental Health Practice. Vol. I. Analytical Aspects and Health Significance. Vol. II. Determination of Individual Elements. CRC Press, Boca Raton, FL, 1983.Google Scholar
  22. 23.
    Taylor A: Usefulness of measurements of trace elements in hair. Ann Clin Biochem 23:364–378, 1986.PubMedGoogle Scholar
  23. 24.
    Goyer RA, Rhyne BC: Pathological effects of lead. Internat Rev Pathol 12:1–77, 1973.Google Scholar
  24. 25.
    Posner HS, Damstra T, Nriagu JO: Human health effects of lead, In: The Biogeochemistry of Lead in the Environment. Nriagu JO (ed): Elsevier/North-Holland Biomedical Press, Amsterdam, 1978, pp. 173–223.Google Scholar
  25. 26.
    Hirano A, Iwata M: Neuropathology of lead intoxication, in Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. North-Holland Biomedical Press, Amsterdam, 36:35–64, 1979.Google Scholar
  26. 27.
    Cullen MR, Robins JM, Eskenazi B: Adult inorganic lead intoxication: presentation of 31 new cases and a review of recent advances in the literature. Medicine 62:221–247, 1983.PubMedGoogle Scholar
  27. 28.
    Beritic T: Lead neuropathy. CRC Crit Rev Toxicol 12:149–213, 1984.Google Scholar
  28. 29.
    Goyer RA: Lead Toxicity: A problem in environmental pathology. Am J Path 64:167–179, 1971.PubMedGoogle Scholar
  29. 30.
    Browder AA, Joselow MM, Louria DB: The problem of lead poisoning. Medicine 52:121–139, 1973.PubMedGoogle Scholar
  30. 31.
    Fell GS: Lead toxicity: problems of definition and laboratory evaluation. Ann Clin Biochem 21:453–460, 1984.PubMedGoogle Scholar
  31. 32.
    Taylor JR: Neurotoxicity of certain environmental substances. Clinics Lab Med 4:489–497, 1984.Google Scholar
  32. 33.
    Lin-Fu JS: Historical perspective on health effects of lead. In Dietary and Environmental Lead: Human Health Effects. Mahaffey KR, (ed): Elsevier Science Publishers B.V. Amsterdam, (Biomedical Div), 1985, pp. 43–63.Google Scholar
  33. 34.
    Aub JC, Fairhill LT, Minot AS, et al. Lead poisoning. Medicine 4:1–250, 1925.Google Scholar
  34. 35.
    Morgan JM, Hartley MW, Miller RE: Nephropathy in chronic lead poisoning. Arch Intern Med 118:17–29, 1966.PubMedGoogle Scholar
  35. 36.
    Cooper GP, Sigwart CD: Neurophysiological effects of lead. In Lead Toxicity. Singhai RL, Thomas JA (eds): Urban and Schwarzenberg, Baltimore, 1980, pp. 401–423.Google Scholar
  36. 37.
    Feldman R, Hayes MK, Younes R, et al: Lead neuropathy in adults and children. Arch Neurol 34:481–488, 1977.PubMedGoogle Scholar
  37. 38.
    Baker EL, Landrigan PJ, Barbour AG, et al. Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead levels. Br J Indust Med 36:314–322, 1979.Google Scholar
  38. 39.
    Hyslop GH, Kraus WM: The pathology of motor paralysis by lead. Arch Neurol Psych 10:444–455, 1923.Google Scholar
  39. 40.
    Thomas HM: A case of generalized lead paralysis, with a review of the cases of lead palsy seen in the hospital. Johns Hopkins Hosp Bull 15:209–222, 1904.Google Scholar
  40. 41.
    Dejerine-Klumpke J: Des polynevrites en general et des paralysies et atrophies saturnines en particuliere. Paris, 1889.Google Scholar
  41. 42.
    Dejerine J: Recherches sur les lesions du systeme nerveux dans la paralysie saturnine. Compt Rend Soc de Biol series 7,1:11–17, 1879.Google Scholar
  42. 43.
    Gombault A: Contribution a l’histoire anatomique de l’atrophie musculaire saturnine. Arch Physiol Norm 5:592, 1873.Google Scholar
  43. 44.
    Tanquerel des Planches L.: Lead Diseases. Translated and edited by Dana SL, Daniel Bixby, Lowell, MA, 1839.Google Scholar
  44. 45.
    Seto DS, Freeman JM: Lead neuropathy in childhood. Amer J Dis Child 107:337–342, 1964.PubMedGoogle Scholar
  45. 46.
    Catton MJ, Harrison MJG, Fullerton PM, et al: Subclinical neuropathy in lead workers. Brit Med 7 2:80–82, 1970.Google Scholar
  46. 47.
    Seppalainen AM, Hernberg S: Sensitive technique for detecting subclinical lead neuropathy. Brit J Industr Med 29:443–449, 1972.PubMedGoogle Scholar
  47. 48.
    Seppalainen AM, Tola S, Hernberg S, et al: Subclinical neuropathy at “safe” levels of lead exposure. Arch Environ Health 30:180–183, 1975.PubMedGoogle Scholar
  48. 49.
    Buchthal F, Behse F: Electrophysiology and nerve biopsy in men exposed to lead. Brit J Indust Med 36:135–147, 1979.Google Scholar
  49. 50.
    Ashby JAS: A neurological and biochemical study of early lead poisoning. Brit J Indust Med 37:133–140, 1980.Google Scholar
  50. 51.
    Seppalainen AM, Hernberg S: Subclinical lead neuropathy. Amer J Indust Med 1:413–420, 1980.Google Scholar
  51. 52.
    Valciukas JA, Lilis R, Singer R, et al: Lead exposure and behavioral changes: comparisons of four occupational groups with different levels of lead absorption. Amer J Indust Med 1:421–426, 1980.Google Scholar
  52. 53.
    Bordo B, Massetto N, Musicco M, et al: Electrophysiologic changes in workers with “low” blood lead levels. Amer J Indust Med 3:23–32, 1982.Google Scholar
  53. 54.
    Seppalainen AM, Hernberg S, Vesanto R, et al: Early neurotoxic effects of occupational lead exposure: a prospective study. NeuroToxicol 4:181–192, 1983.Google Scholar
  54. 55.
    Singer R, Valciukas JA, Lilis R: Lead exposure and nerve conduction velocity: the differential time course of sensory and motor nerve effects. NeuroToxicol 4:193–202, 1983.Google Scholar
  55. 56.
    Triebig G, Weltle D, Valentin H: Investigations on neurotoxicity of chemical substances at the workplace. Int Arch Occup Environ Health 53:189–204, 1984.PubMedGoogle Scholar
  56. 57.
    Corsi G, Bartolucci GB, Fardin P, et al: Biochemical and electrophysiological study of subjects with a history of past lead exposure. Amer J Indust Med 6:281–290, 1984.Google Scholar
  57. 58.
    Bini L, Bollea G: Fatal poisoning by lead-benzine (A clinico-pathologic study), J Neuropathol Exp Neurol 6:271–278, 1947.PubMedGoogle Scholar
  58. 59.
    Cassells DAK, Dodds EC: Tetra-ethyl lead poisoning. Brit Med J 2:681–685, 1946.PubMedGoogle Scholar
  59. 60.
    Noms C, Gettler A: Poisoning by tetra-ethyl lead: Postmortem and chemical findings. J Am Med Assoc 85:818–820, 1925.Google Scholar
  60. 61.
    Sanders LW: Tetraethyllead intoxication. Arch Environm Health 8:270–277, 1964.Google Scholar
  61. 62.
    Beattie AD, Moore MR, Goldberg A: Tetraethyllead poisoning. Lancet 2:12–15, 1972.PubMedGoogle Scholar
  62. 63.
    Valpey R, Sumi SM, Copass MK, et al: Acute and chronic progressive encephalopathy due to gasoline sniffing. Neurology 28:507–510, 1978.PubMedGoogle Scholar
  63. 64.
    Lampert PW, Schochet SS: Demyelination and remyelination in lead neuropathy. J Neuropathol Exp Neurol 27:527–545, 1968.PubMedGoogle Scholar
  64. 65.
    Schlaepfer WW: Experimental lead neuropathy: a disease of the supporting cells in the peripheral nervous system. J Neuropathol Exp Neurol 28:401–418, 1969.PubMedGoogle Scholar
  65. 66.
    Low PA, Dyck PJ: Increased endoneurial fluid pressure in experimental lead neuropathy. Nature 269:427–428, 1977.PubMedGoogle Scholar
  66. 67.
    Ohnishi A, Schilling K, Brimijoin WS, et al: Lead neuropathy 1. Morphometry, nerve conduction, and choline acetyltransferase transport: New finding of endoneurial edema associated with segmental demyelination. J Neuropathol Exp Neurol 36:499–518, 1977.PubMedGoogle Scholar
  67. 68.
    Dyck PJ, O’Brien PC, Ohnishi A: Lead neuropathy: 2. Random distribution of segmental demyelination among “old internodes” of myelinated fibers. J Neuropathol Exp Neurol 36:570–575, 1977.PubMedGoogle Scholar
  68. 69.
    Myers RR, Powell HC, Shapiro HM, et al: Changes in endoneurial fluid pressure, permeability, and peripheral nerve ultrastructure in experimental lead neuropathy. Ann Neurol 8:392–401, 1980.PubMedGoogle Scholar
  69. 70.
    Windebank AJ, McCall JT, Hunder HG, et al: The endoneurial content of lead related to the onset and severity of segmental demyelination. J Neuropathol Exp Neurol 39:692–699, 1980.PubMedGoogle Scholar
  70. 71.
    Dyck PJ, Windebank AJ, Low PA, et al: Blood nerve barrier in rat and cellular mechanisms of lead-induced segmental demyelination. J Neuropathol Exp Neurol 39:700–709, 1980.PubMedGoogle Scholar
  71. 72.
    Windebank AJ, Dyck PJ: Kinetics of 210 Pb entry into the endoneurium. Brain Res 225:67–73, 1981.PubMedGoogle Scholar
  72. 73.
    Ohnishi A, Dyck PJ: Retardation of Schwann cell division and axonal regrowth following nerve crush in experimental lead neuropathy. Ann Neurol 10:469–477, 1981.PubMedGoogle Scholar
  73. 74.
    Poduslo JF, Low PA, Windebank AJ, et al: Altered blood-nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration. J Neurosci 2:1507–1514, 1982.PubMedGoogle Scholar
  74. 75.
    Powell HC, Myers RR, Lampert PW: Changes in Schwann cells and vessels in lead neuropathy. Am J Pathol 109:193–205, 1982.PubMedGoogle Scholar
  75. 76.
    Windebank AJ, Dyck PJ: Localization of lead in rat peripheral nerve by electron microscopy. Ann Neurol 18:197–201, 1985.PubMedGoogle Scholar
  76. 77.
    Coria F, Berciano MT, Berciano J, et al: Axon membrane remodeling in the lead-induced demyelinating neuropathy of the rat. Brain Res 291:369–372, 1984.PubMedGoogle Scholar
  77. 78.
    Coria F, Silos I, Fernandez R, et al: Demyelina-tion-induced plasticity in the axon membrane: an ultrastructural cytochemical study of lead neuropathy in the rat. Neurosci Letters 58:359–364, 1985.Google Scholar
  78. 79.
    Meiri H, Pri-chen S, Korczyn AD: Sodium channel localization in rat sciatic nerve following lead-induced demyelination. Brain Res 359:326–331, 1985.PubMedGoogle Scholar
  79. 80.
    Bouldin TW, Meighan ME, Gaynor JJ, et al: Differential vulnerability of mixed and cutaneous nerves in lead neuropathy. J Neuropathol Exp Neurol 44:384–396, 1985.PubMedGoogle Scholar
  80. 81.
    Gombault A: Contribution a l’etude anatomique de la neurite parenchymateuse subaigue et chronique-neurite segmentaire periaxile. Arch Neurol (Paris) 1:11–38, 177–190, 1880–1881.Google Scholar
  81. 82.
    Fullerton PM: Chronic peripheral neuropathy produced by lead poisoning in guinea-pigs. J Neuropathol Exp Neurol 25:214–236, 1966.PubMedGoogle Scholar
  82. 83.
    Anders E, Dietz DD, Bagnell CR, et al: Morphological, pharmacokinetic, and hematological studies of lead-exposed pigeons. Environm Res 28:344–363, 1982.Google Scholar
  83. 84.
    Steiss JE, Braund KG, Clark EG: Inability to experimentally produce a polyneuropathy in dogs given chronic oral low level lead. Can J Comp Med 49:401–404, 1985.PubMedGoogle Scholar
  84. 85.
    Choie DD, Richter GW: Effects of lead on the kidney. In: Lead Toxicity. Singhai RL, Thomas JA (eds) Munich, Urban and Schwarzenberg, Baltimore, 1980, pp. 187–212.Google Scholar
  85. 86.
    Goyer RA, May P, Cates MM, et al: Lead and protein content of isolated intranuclear inclusion bodies from kidneys of lead-poisoned rats. Lab Invest 22:245–251, 1970.PubMedGoogle Scholar
  86. 87.
    Schepers GWH: Tetraethyllead and tetramethyl-lead. Arch Env Health 8:277–295, 1964.Google Scholar
  87. 88.
    Davis RK, Horton AW, Larson EE, et al: Inhalation of tetramethyllead and tetraethyllead. Arch Env Health 6:473–479, 1963.Google Scholar
  88. 89.
    Sobue G, Pleasure D: Experimental lead neuropathy: inorganic lead inhibits proliferation but not differentiation of Schwann cells. Ann Neurol 17:462–468, 1985.PubMedGoogle Scholar
  89. 90.
    Scott B, Lew J: Chronic exposure to lead causes persistent alterations in the electric membrane properties of neurons in cell culture. J Neurobiol 16:425–433, 1985.PubMedGoogle Scholar
  90. 91.
    Bull RJ: Lead and energy metabolism. In: Lead Toxicity. Singhal RL, Thomas JA (eds): Urban and Schwarzenberg, Baltimore, 1980, pp. 119–168.Google Scholar
  91. 92.
    Kober TE, Cooper GP: Lead competitively inhibits calcium-dependent synaptic transmission in the bullfrog sympathetic ganglion. Nature 262:704–705, 1976.PubMedGoogle Scholar
  92. 93.
    Winder C, Kitchen I: Lead neurotoxicity: a review of the biochemical, neurochemical and drug induced behavioural evidence. Prog Neurobiol 22:59–87, 1984.PubMedGoogle Scholar
  93. 94.
    Joselow MM, Louria DB, Browder AA: Mercurialism: environmental and occupational aspects. Ann Int Med 76:119–130, 1972.PubMedGoogle Scholar
  94. 95.
    Chang LW: Neurotoxic effects of mercury—a review. Environm Res 14:329–373, 1977.Google Scholar
  95. 96.
    Chang LW: Mercury. In: Experimental and Clinical Neurotoxicology. Spencer PS, Schaumburg HH (eds). Williams and Wilkins, Baltimore, 1980, pp. 508–526.Google Scholar
  96. 97.
    Tedeschi LG: The Minamata disease. Amer J Foren Med Pathol 3:335–338, 1982.Google Scholar
  97. 98.
    Winship KA: Toxicity of mercury and its inorganic salts. Adv Drug React Ac Pois Rev 3:129–160, 1985.Google Scholar
  98. 99.
    Takeuchi T, Kambara T, Morikawa N, et al: Histological studies of an encephalopathy from an unknown cause in Minamata district of Kyushu prefecture. Acta Pathol Jap 7:602–611, 1957.Google Scholar
  99. 100.
    Kitamura S, Katsuki S, Kawamori Y, et al: Epidemiological studies of an unknown nervous disease occurring in the Minamata district. Kumamoto Med J 31:1–19 (suppl 1); 31:70–74 (suppl 2), 1957. (in Japanese)Google Scholar
  100. 101.
    Katsuki S, Tokuomi H, Huai S, et al: On a disease of the central nervous system occurring in the Minamata area of Kumamoto prefecture, Japan J Kumamoto Med Soc 31:23–36 (suppl 1); 31:251–261 (suppl 2), 1957. (in Japanese)Google Scholar
  101. 102.
    McAlpine D, Araki S: Minamata disease: an unusual neurological disorder caused by contaminated fish. Lancet 2:629–631, 1958.PubMedGoogle Scholar
  102. 103.
    McAlpine D, Araki S: Minamata disease: late effects of an unusual neurological disorder caused by contaminated fish. Arch Neurol 1:522–530, 1959.Google Scholar
  103. 104.
    Kurland LT, Faro SN, Siedler H: Minamata disease: The outbreak of a neurologic disorder in Minamata, Japan, and its relationship to the ingestion of seafood contaminated by mercuric compounds. World Neurol 1:370–391, 1960.PubMedGoogle Scholar
  104. 105.
    Takeuchi T, Morikawa N, Matsumoto H, et al: A pathological study of Minamata disease in Japan. Acta Neuropathol 2:40–57, 1962.Google Scholar
  105. 106.
    Takeuchi T: Pathology of Minamata disease. Acta Pathol Jpn 32:73–99 (suppl 1), 1982.PubMedGoogle Scholar
  106. 107.
    Hunter D, Bomford RR, Russell DS: Poisoning by methyl mercury compounds. Quart J Med new series 9:193–213, 1940.Google Scholar
  107. 108.
    Eto K, Takeuchi T: Pathological changes of human sural nerves in Minamata disease (meth-ylmercury poisoning). Virch Arch B 23:109–128, 1977.Google Scholar
  108. 109.
    Tokuomi H, Uchino M, Imamura S, et al: Minamata disease (organic mercury poisoning): Neuroradiologic and electrophysiologic studies. Neurol 32:1369–1375, 1982.Google Scholar
  109. 110.
    Nagaki J, Ohnishi A, Kuroiwa Y: Electrophysiologic and histopathologic studies on sural nerves from Minamata disease patients of delayed onset showing distal sensory impairments. Clin Neurol 25:88–94, 1985.Google Scholar
  110. 111.
    Tamashiro H, Arakaki M, Akagi H, et al: Mortality and survival for Minamata disease. Inter J Epidemiol 14:582–588, 1985.Google Scholar
  111. 112.
    Sato T, Ikuta F: Neuropathology of methylmer-cury intoxication in Niigata and chronic effect in monkeys. In: Neurotoxicology, Roizin L, Shiraki H, Grcevic N, (eds): Raven Press, New York, 1977, pp. 261–269.Google Scholar
  112. 113.
    Bakir F, Damluji SF, Amin-Zaki L, et al: Methylmercury poisoning in Iraq. Science 181:230–241, 1973.PubMedGoogle Scholar
  113. 114.
    Le Quesne PM, Damluji SF, Rustam H: Electrophysiological studies of peripheral nerves in patients with organic mercury poisoning J Neurol Neurosurg Psych 37:333–339, 1974.Google Scholar
  114. 115.
    Rustam H, Hamdi T: Methyl mercury poisoning in Iraq: a neurological study. Brain 97:499–510, 1974.Google Scholar
  115. 116.
    Von Burg R, Rustam H: Electrophysiological investigations of methylmercury intoxication in humans. Evaluation of peripheral nerve by conduction velocity and electromyography. Elec-troenceph Clin Neurophys 37:381–392, 1974.Google Scholar
  116. 117.
    Kark RAP, Poskanzer DC, Bullock JD, et al: Mercury poisoning and its treatment with N-acetyl-D, L-penicillamine. N Eng J Med 285:10–16, 1971.Google Scholar
  117. 118.
    Snodgrass W, Sullivan JB, Rumack BH, et al: Mercury poisoning from home gold ore processing: use of penicillamine and dimercaprol. J Am Med Assoc 246:1929–1931, 1981.Google Scholar
  118. 119.
    Vroom FQ, Greer M: Mercury vapour intoxication. Brain 95:305–318, 1972.PubMedGoogle Scholar
  119. 120.
    Iyer K, Goodgold J, Eberstein A, et al: Mercury poisoning in a dentist. Arch Neurol 33:788–790, 1976.PubMedGoogle Scholar
  120. 121.
    Feldman RG: Neurological manifestations of mercury intoxication. Acta Neurol Scand 66, Supp 92:201–209, 1982.Google Scholar
  121. 122.
    Okinaka S, Yoshikawa M, Mozai T, et al: Encephalomyelopathy due to an organic mercury compound. Neurol 14:69–76, 1964.Google Scholar
  122. 123.
    Chang LW: Pathological effects of mercury poisoning, in Nriagu JO (ed.): The Biogeochemistry of Mercury in the Environment. Elsevier/North Holland, Amsterdam, 1979, pp. 519–579.Google Scholar
  123. 124.
    Davis LE, Wands JR, Weiss SA, et al: Central nervous system intoxication from mercurous chloride laxatives: quantitative, histochemical, and ultrastructural studies. Arch Neurol 30:428–431, 1974.PubMedGoogle Scholar
  124. 125.
    Triebig G, Schaller KH: Neurotoxic effects in mercury-exposed workers. Neurobehav Toxicol Teratol 4:717–720, 1982.PubMedGoogle Scholar
  125. 126.
    Levine SP, Cavender GD, Langolf GD, et al: Elemental mercury exposure: peripheral neurotoxicity. Brit J Indust Med 39:136–139, 1982.Google Scholar
  126. 127.
    Albers JW, Cavender GD, Levine SP, et al: Asymptomatic sensorimotor polyneuropathy in workers exposed to elemental mercury. Neurol 33:1168–1174, 1982.Google Scholar
  127. 128.
    Adams CR, Ziegler DK, Lin JT: Mercury intoxication simulating amyotrophic lateral sclerosis. J Am Med Assoc 250:642–643, 1983.Google Scholar
  128. 129.
    Brown, IA: Chronic mercurialism. Arch Neurol Psych 72:674–681, 1954.Google Scholar
  129. 130.
    Kantarjian AD: A syndrome clinically resembling amyotrophic lateral sclerosis following chronic mercurialism. Neurol 11:639–644, 1961.Google Scholar
  130. 131.
    Chang LW, Opitz JM, Pallister PD, et al: Minamata disease: a case report and a comparative study. Acta Neuropathol 26:275–284, 1973.PubMedGoogle Scholar
  131. 132.
    Takeuchi T: Neuropathology of Minamata disease in Kumamoto: especially at the chronic stage. In: Neurotoxicology. Roizin L, Shiraki H, Grcevic N (eds): Raven Press, New York, 1977, pp. 235–246.Google Scholar
  132. 133.
    Wheatley B, Barbeau A, Clarkson TW, et al: Methylmercury poisoning in Canadian Indians— the elusive diagnosis. J Can Neurol Sci 6:417–422, 1979.Google Scholar
  133. 134.
    Yoshino Y, Mozai T, Nakao K: Distribution of mercury in the brain and its subcellular units in experimental organic mercury poisonings. J Neurochem 13:397–406, 1966.Google Scholar
  134. 135.
    Chang LW, Yamaguchi S, Dudley AW: Neurological changes in cats following long-term diet of mercury contaminated tuna. Acta Neuropathol 27:171–176, 1974.PubMedGoogle Scholar
  135. 136.
    Jacobs JM, Carmichael N, Cavanagh JB: Ultra-structural changes in the nervous system of rabbits poisoned with methyl mercury. Toxicol Appl Pharmacol 39:249–261, 1977.PubMedGoogle Scholar
  136. 137.
    Carmichael N, Cavanagh JB, Rodda RA: Some effects of methyl mercury salts on the rabbit nervous system. Acta Neuropathol 32:115–125, 1975.PubMedGoogle Scholar
  137. 138.
    Miyakawa T, Deshimaru M: Electron microscopical study of experimentally induced poisoning due to organic mercury compound. Acta Neuropathol 14:126–136, 1969.PubMedGoogle Scholar
  138. 139.
    Miyakawa T, Deshimaru M, Sumiyoshi S, et al: Experimental organic mercury poisoning— pathological changes in peripheral nerves. Acta Neuropathol 15:45–55, 1970.PubMedGoogle Scholar
  139. 140.
    Cavanagh JB, Chen FCK: The effects of methyl-mercury-dicyandiamide on the periperhal nerves and spinal cord of rats. Acta Neuropathol 19:208–215, 1971.PubMedGoogle Scholar
  140. 141.
    Cavanagh JB, Chen FCK: Amino acid incorporation in protein during the “silent phase” before organo-mercury and p-bromophenylacetylurea neuropathy in the rat. Acta Neuropathol 19:216–224, 1971.PubMedGoogle Scholar
  141. 142.
    Klein R, Herman SP, Brubaker PE, et al: A model of acute methyl mercury intoxication in rats. Arch Pathol 93:408–418, 1972.PubMedGoogle Scholar
  142. 143.
    Chang LW, Hartmann HA: Ultrastructural studies of the nervous system after mercury intoxication: pathological changes in the nerve cell bodies. Acta Neuropathol 20:122–138, 1972.PubMedGoogle Scholar
  143. 144.
    Chang LW, Hartmann HA: Ultrastructural studies of the nervous system after mercury intoxication: pathological changes in the nerve fibers. Acta Neuropathol 20:316–334, 1972.PubMedGoogle Scholar
  144. 145.
    Chang LW, Hartmann HA: Electron microscopic histochemical study on the localization and distribution of mercury in the nervous system after mercury intoxication. Exp Neurol 35:122–137, 1972.PubMedGoogle Scholar
  145. 146.
    Somjen GG, Herman SP, Klein R: Electrophysi-ology of methyl mercury poisoning. J Pharmacol Exp Therap 186:579–592, 1973.Google Scholar
  146. 147.
    Herman SP, Klein R, Talley FA, et al: An ultra-structural study of methylmercury-induced primary sensory neuropathy in the rat. Lab Invest 28:104–118, 1973.PubMedGoogle Scholar
  147. 148.
    Jacobs JM, Carmichael N, Cavanagh JB: Ultra-structural changes in the dorsal root and trigeminal ganglia of rats poisoned with methyl mercury. Neuropathol App Neurobiol 1:1–19, 1975.Google Scholar
  148. 149.
    Carmichael N, Cavanagh JB: Autoradiographic localisation of 3H-Uridine in spinal ganglion neurones of the rat and the effects of methyl mercury poisoning. Acta Neuropathol 34:137–148, 1976.PubMedGoogle Scholar
  149. 150.
    Miyakawa T, Shimoji A, Kuramoto R, et al: Morphological observations of peripheral nerves by the scanning electron microscope. Folia Psychiat Neurol Jpn 35:501–506, 1981.PubMedGoogle Scholar
  150. 151.
    Ornata S, Momose Y, Ueki H, et al: In vivo effect of methylmercury on protein synthesis in peripheral nervous tissues of the rat. Arch Toxicol 49:203–214, 1982.Google Scholar
  151. 152.
    Somjen GG, Herman SP, Klein R, et al: The uptake of methyl mercury (203Hg) in different tissues related to its neurotoxic effects. J Pharmacol Exp Therap 187:602–611, 1973.Google Scholar
  152. 153.
    Change LW, Hartmann HA: Blood-brain barrier dysfunction in experimental mercury intoxication. Acta Neuropathol 21:179–184, 1972.Google Scholar
  153. 154.
    Ware RA, Chang LW, Burkholder PM: An ultra-structural study on the blood-brain barrier dysfunction following mercury intoxication. Acta Neuropathol 30:211–224, 1974.PubMedGoogle Scholar
  154. 155.
    Yoshino Y, Mozai T, Nakao K: Biochemical changes in the brain in rats poisoned with an alkylmercury compound, with special reference to the inhibition of protein synthesis in brain cortex slices. J Neurochem 13:1223–1230, 1966.PubMedGoogle Scholar
  155. 156.
    Brubaker PE, Klein R, Herman SP, et al: DNA, RNA, and protein synthesis in brain, liver, and kidneys of asymptomatic methylmercury treated rats. Exp Molec Pathol 18:263–280, 1973.Google Scholar
  156. 157.
    Chang LW, Desnoyers PA, Hartmann HA: Quantitative cytochemical studies of RNA in experimental mercury poisoning. I. Changes in RNA content. J Neuropathol Exp Neurol 31:489–501, 1972.PubMedGoogle Scholar
  157. 158.
    Paterson RA, Usher DR: Acute toxicity of methyl mercury on glycolytic intermediates and adenine nucleotides of rat brain. Life Sci 10:121–128, 1971.Google Scholar
  158. 159.
    Salvaterra P, Lown B, Morganti J, et al: Alterations in neurochemical and behavioural parameters in the mouse induced by low doses of methyl mercury. Acta Pharmacol Toxicol 33:177–190, 1973.Google Scholar
  159. 160.
    Kumamoto T, Fukuhara N, Miyatake T, et al: Experimental neuropathy induced by methyl mercury compounds: autoradiographic study of GABA uptake by dorsal root ganglia. Eur Neurol 25:269–277, 1986.PubMedGoogle Scholar
  160. 161.
    Onta M: Ultrastructure of sural nerve in a case of arsenical neuropathy. Acta Neuropathol 16:233–242, 1970.Google Scholar
  161. 162.
    Le Quesne PM, McLeod JG: Peripheral neuropathy following a single exposure to arsenic. J Neurol Sci 32:437–451, 1977.PubMedGoogle Scholar
  162. 163.
    Landrigan PJ: Occupational and community exposures to toxic metals: Lead, cadmium and arsenic. West J Med 137:531–539, 1982.PubMedGoogle Scholar
  163. 164.
    Hessl SM, Berman E: Severe peripheral neuropathy after exposure to monosodium methyl arsonate. J Toxicol Clin Toxicol 19:281–287, 1982.PubMedGoogle Scholar
  164. 165.
    Heyman A, Pfeiffer JB, Willett RW, et al: Peripheral neuropathy caused by arsenical intoxication. New Eng J Med 254:401–409, 1956.PubMedGoogle Scholar
  165. 166.
    Jenkins RB: Inorganic arsenic and the nervous system. Brain 89:479–498, 1966.PubMedGoogle Scholar
  166. 167.
    Squibb KS, Fowler BA: The toxicity of arsenic and its compounds, in Fowler BA (ed): Biological and Environmental Effects of Arsenic. Elsevier, Amsterdam, 1983, pp. 233–270.Google Scholar
  167. 168.
    Dinman BD: Arsenic: chronic human intoxication. J Occup Med 2:137–141, 1960.Google Scholar
  168. 169.
    Chhuttani PN, Chawla LS, Sharma TD: Arsenical neuropathy. Neurol 17:269–274, 1967.Google Scholar
  169. 170.
    Telerman-Toppet N, Flament-Durand J, Khou-besserian P, et al: Encephalomyeloneuropathy in acute arsenic poisoning: an ultrastructural study of the sural nerve. Clin Neuropathol 1:47–54, 1982.PubMedGoogle Scholar
  170. 171.
    Mackell MA, Poklis A, Gantner GE, et al: An unsuspected arsenic poisoning murder disclosed by forensic autopsy. Amer J Foren Med Pathol 6:358–361, 1985.Google Scholar
  171. 172.
    Cebrian ME, Albores A, Aguilar M, et al: Chronic arsenic poisoning in the north of Mexico. Human Toxicol 2:121–133, 1983.Google Scholar
  172. 173.
    Kreiss K, Zack MM, Feldman RG, et al: Neurologic evaluation of a population exposed to arsenic in Alaskan well water. Arch Environm Health 38:116–121, 1983.Google Scholar
  173. 174.
    Murphy MJ, Lyon LW, Taylor JW: Subacute arsenic neuropathy: clinical and electrophysiological observations. J Neurol Neurosurg Psych 44:896–900, 1981.Google Scholar
  174. 175.
    Hassin GB: Symptomatology of arsenical polyneuritis. J Nerv Ment Dis 72:628–636, 1930.Google Scholar
  175. 176.
    Danan M, Conso F, Dally S, et al: Intoxication par l’anhydride arsenieux. Neuropathie peripherique et alteration des fonctions cognitives. Ann Med Interne 136:479–481, 1985.Google Scholar
  176. 177.
    Feldman RG, Niles CA, Kelly-Hayes M, et al: Peripheral neuropathy in arsenic smelter workers. Neurol 29:936–944, 1979.Google Scholar
  177. 179.
    Blom S, Lagerkvist B, Linderholm H: Arsenic exposure to smelter workers: clinical and neurophysiological studies. Scand J Work Environ Health 11:265–269, 1985.PubMedGoogle Scholar
  178. 179.
    Harding JDJ, Lewis G, Done JT: Experimental arsanilic acid poisoning in pigs. Vet Rec 83:560–564, 1968.PubMedGoogle Scholar
  179. 180.
    Brown MM, Rhyne BC, Goyer RA, et al: Intracellular effects of chronic arsenic administration on renal proximal tubule cells. J Toxicol Environm health 1:505–514, 1976.Google Scholar
  180. 181.
    Munch JC, Ginsburg HM, Nixon CE: The 1932 thallotoxicosis outbreak in California. J Am Med Assoc 100:1315–1319, 1933.Google Scholar
  181. 182.
    Munch JC: Human thallotoxicosis. J Am Med Assoc 102:1929–1934.Google Scholar
  182. 183.
    Gettler AO, Weiss L: Thallium poisoning. III. Clinical toxicology of thallium. Amer J Clin Pathol 13:422–429, 1943.Google Scholar
  183. 184.
    Grunfeld O, Hinostroza G: Thallium poisoning. Arch Int Med 114:132–138, 1964.Google Scholar
  184. 185.
    Smith DH, Doherty RA: Thallitoxicosis: report of three cases in Massachusetts. Pediatr 34:480–490, 1964.Google Scholar
  185. 186.
    Gastel B: Thallium poisoning. Johns Hopkins Med J 142:21–31, 1978.Google Scholar
  186. 187.
    Moeschlin S: Thallium poisoning. Clin Toxicol 17:133–146, 1980.PubMedGoogle Scholar
  187. 188.
    Saddique A, Peterson CD: Thallium poisoning: a review. Vet Hum Toxicol 25:16–22, 1983.PubMedGoogle Scholar
  188. 189.
    Bank WJ, Pleasure DE, Suzuki K, et al: Thallium poisoning. Arch Neurol 26:456–464, 1972.PubMedGoogle Scholar
  189. 190.
    Kennedy P, Cavanagh JB: Spinal changes in the neuropathy of thallium poisoning. J Neurol Sci 29:295–301, 1976.PubMedGoogle Scholar
  190. 191.
    Davis LE, Standefer JC, Kornfeld M, et al: Acute thallium poisoning: Toxicological and morphological studies of the nervous system. Ann Neurol 10:38–44, 1981.PubMedGoogle Scholar
  191. 192.
    Cavanagh JB, Fuller NH, Johnson HRM, et al: The effects of thallium salts, with particular reference to the nervous system changes. Quart J Med, new series 170:293–319, 1974.Google Scholar
  192. 193.
    Andersen O: Clinical evidence and therapeutic indications in neurotoxicology, exemplified by thallotoxicosis. Acta Neurol Scand suppl 100:185–192, 1984.Google Scholar
  193. 194.
    Reed D, Crawley J, Faro SN, et al: Thallotoxicosis: acute manifestations and sequelae. J Am Med Assoc 183:516–522, 1963.Google Scholar
  194. 195.
    Barnes MB, Murray K, Tilley PJB: Neurological deficit more than thirty years after chronic thallium intoxication. Lancet 1:562, 1984.PubMedGoogle Scholar
  195. 196.
    Kennedy P, Cavanagh JB: Sensory neuropathy produced in the cat with thallous acetate. Acta Neuropathol 39:81–88, 1977.PubMedGoogle Scholar
  196. 197.
    Herman MM, Bensch KG: Light and electron microscopic studies of acute and chronic thallium intoxication in rats. Toxicol Appl Pharmacol, 10:199–222, 1967.PubMedGoogle Scholar
  197. 198.
    Spencer PS, Peterson ER, Madrid R, et al: Effects of thallium salts on neuronal mitochondria in organotypic cord-ganglia-muscle combination cultures. J Cell Biol 58:79–95, 1973.PubMedGoogle Scholar
  198. 199.
    Woods JS, Fowler BA: Alteration of hepatocellular structure and function by thallium chloride: ultrastructural, morphometric, and biochemical studies. Toxicol Appl Pharmacol 83:218–229, 1986.PubMedGoogle Scholar
  199. 200.
    Melnick RL, Monti LG, Motzkin SM: Uncoupling of mitochondrial oxidative phosphorylation by thallium. Biochem Biophys Res Comm 69:68–73, 1976.PubMedGoogle Scholar
  200. 201.
    Wiegand H, Papadopoulos R, Csicsaky M, et al: The action of thallium acetate on spontaneous transmitter release in the rat neuromuscular junction. Arch Toxicol 55:253–257, 1984.PubMedGoogle Scholar
  201. 202.
    Rosenberg B, Van Camp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699, 1965.PubMedGoogle Scholar
  202. 203.
    Rozencweig M, Von Hoff DD, Slavik M, et al: Cisdiamminedichloroplatinum (II): a new anticancer drug. Ann Int Med 86:803–812, 1977.PubMedGoogle Scholar
  203. 204.
    Rosenberg B: Fundamental studies with cisplatin. Cancer 55:2303–2316, 1985.PubMedGoogle Scholar
  204. 205.
    Higby DJ, Wallace JH, Holland JF: Cisdiamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 57:459–463, 1973.PubMedGoogle Scholar
  205. 206.
    Lippman AJ, Helson C, Helson L, et al: Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 57:191–200, 1973.PubMedGoogle Scholar
  206. 207.
    Prestayko AW, D’Aoust JC, Issell BF, et al: Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 6:17–39, 1979.PubMedGoogle Scholar
  207. 208.
    Hall DJ, Diasio R, Goplerud DR: Cis-platinum in gynecologic cancer. III. Toxicity. Am J Obstet Gynecol 141:309–312, 1981.PubMedGoogle Scholar
  208. 209.
    Loehrer PJ, Einhorn LH: Cisplatin. Ann Int Med 100:704–713, 1984.PubMedGoogle Scholar
  209. 210.
    Kopf-Maier P, Kopf H: Crostatische Platin-Komplexe: eine unerwartete Entdeckung mit weitreichenden Konsequenzen. Naturwiss 73: 239–247, 1986.PubMedGoogle Scholar
  210. 211.
    Reedijk J, Lohman PHM: Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl 7:173–180, 1985.Google Scholar
  211. 212.
    Von Hoff DD, Schilsky R, Reichert CM, et al: Toxic effects of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1527–1531, 1979.Google Scholar
  212. 213.
    Kedar A, Cohen ME, Freeman AI: Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: case report. Cancer Treat Rep 62:819–821, 1978.PubMedGoogle Scholar
  213. 214.
    Hadley D, Herr HW: Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment. Cancer 44:2026–2028, 1979.PubMedGoogle Scholar
  214. 215.
    Von Hoff DD, Reichert CM, Cuneo R, et al: Demyelination of peripheral nerves associated with cis-diamminedichloroplatinum (II) (DDP) therapy. Proc Am Assn Ca Res 20:91, 1979.Google Scholar
  215. 216.
    Marin AC, Rierson B: Peripheral neuropathy secondary to cis-dichlorodiammineplatinum (II) (platinol). Treatment for advanced ovarian cancer. Ariz Med 36:898–899, 1979.PubMedGoogle Scholar
  216. 217.
    Hemphill M, Pestronk A, Walsh T, et al: Sensory neuropathy in cis-platinum chemotherapy. Neurol 30:429, 1980.Google Scholar
  217. 218.
    Reinstein L, Ostrow SS, Wiernik PH: Peripheral neuropathy after cis-platinum (II) (DDP) therapy. Arch Phys Med Rehabil 61:280–282, 1980.PubMedGoogle Scholar
  218. 219.
    Cowan JD, Kies MS, Roth JL, et al: Nerve conduction studies on patients treated with cis-diamminedichloroplatinum (II): a preliminary report. Cancer Treat Rep 64:1119–1122, 1980.PubMedGoogle Scholar
  219. 220.
    Walsh TJ, Clark AW, Parhad IM, et al: Neurotoxic effects of cisplatin therapy. Arch Neurol 39:719–720, 1982.PubMedGoogle Scholar
  220. 221.
    Busse O, Aigner K, Wilimzig H: Peripheral nerve damage following isolated extremity perfusion with cis-platinum. Rec Res Ca Res 86:264–267, 1983.Google Scholar
  221. 222.
    Roelofs RI, Hrushesky W, Rogin J, et al: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurol 34:934–938, 1984.Google Scholar
  222. 223.
    Thompson, SW, Davis LE, Kornfeld M, et al: Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269–1275, 1984.PubMedGoogle Scholar
  223. 224.
    Legna SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 3:1373–1378, 1985.Google Scholar
  224. 225.
    Gastaut JL, Pellissier JF: Neuropathie au cisplatine etude clinique, electrophysiologique et morphologique. Rev Neurol 141:614–626, 1985.PubMedGoogle Scholar
  225. 226.
    Bagley CM, Rudolph RH, Rivkin SE, et al: Highdose cisplatin therapy for cancer for the ovary: neurotoxicity. Ann Int Med 102:719, 1985.PubMedGoogle Scholar
  226. 227.
    Ongerboer de Visser BW, Tiessens G: Polyneuropathy induced by cisplatin. Prog Exp Tumor Res 29:190–196, 1985.Google Scholar
  227. 228.
    Pages M, Pages AM, Bories-Azeau L: Severe sensorimotor neuropathy after cisplatin therapy. J Neurol Neurosurg Psych 49:333–334, 1986.Google Scholar
  228. 229.
    Dewar J, Lunt H, Abernethy DA, et al: Cisplatin neuropathy with Lhermitte’s sign. J Neurol Neurosurg Psych 49:96–99, 1986.Google Scholar
  229. 230.
    Ashraf M, Scotchel PL, Krall JM, et al: Cis-platinum-induced hypomagnesemia and peripheral neuropathy. Gynec Oncol 16:309–318, 1983.Google Scholar
  230. 231.
    Mabin D, Borsotti JP, Tea S, et al: Neuropathies peripheriques au cours des traitements au cisplatine: etude clinique et electrophysiologique de 11 cas. Rev EEG Neurophysiol Clin 15:341–348, 1985.Google Scholar
  231. 232.
    Carenza L, Villani C, Framarino dei Malatesta ML, et al: Peripheral neuropathy and ototoxicity of dichlorodiamineplatinum: instrumental evaluation. Gynec Oncol 25:244–249, 1986.Google Scholar
  232. 233.
    Rosenfeld CS, Broder LE: Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 68:659–660, 1984.PubMedGoogle Scholar
  233. 234.
    Berman IJ, Mann MP: Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 45:764–766, 1980.PubMedGoogle Scholar
  234. 235.
    Diamond SB, Rudolph SH, Lubicz SS, et al: Cerebral blindness in association with cis-platinum chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol 59:84S–86S, 1982.Google Scholar
  235. 236.
    Cohen RJ, Cuneo RA, Cruciger MP, et al: Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin. J Clin Oncol 1:392–393, 1983.PubMedGoogle Scholar
  236. 237.
    Pomes A, Frusraci S, Cattaino G, et al: Local neurotoxicity of cisplatin after intra-arterial chemotherapy. Acta Neurol Scand 73:302–303, 1986.PubMedGoogle Scholar
  237. 238.
    Kapp JP, Sanford RA: Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of the risk factors. Neurosurgery 19:779–783, 1986.PubMedGoogle Scholar
  238. 239.
    Schaefer SD, Post JD, Close LG, et al: Ototoxicity of low- and moderate-dose cisplatin. Cancer 56:1934–1939, 1985.PubMedGoogle Scholar
  239. 240.
    Melamed LB, Selim MA, Schuchman D: Cisplatin ototoxicity in gynecologic cancer patients. Cancer 55:41–43, 1985.PubMedGoogle Scholar
  240. 241.
    Heischman RW, Stadnicki SW, Ethier MF, et al: Ototoxicity of cis-dichlorodiammine platinum (II) in the guinea pig. Toxicol Appl Pharm 33:320–332, 1975.Google Scholar
  241. 242.
    Nakai Y, Konishi K, Chang KC, et al: Ototoxicity of the anticancer drug cisplatin. Acta Otolaryngol 93:227–232, 1982.PubMedGoogle Scholar
  242. 243.
    Schweitzer VG, Rarey KE, Abrams GE, et al: Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9). Laryngoscope 96:959–974, 1986.PubMedGoogle Scholar
  243. 244.
    Clark A, Parhad I, Griffin JW, et al: Neurotoxicity of cis-platinum: pathology of the central and peripheral nervous systems. Neurol 30:429, 1980.Google Scholar
  244. 245.
    Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol 69:295–308, 1986.PubMedGoogle Scholar
  245. 246.
    246. Blisard KS, Harrington DA, unpublished observations.Google Scholar
  246. 247.
    Rosenberg B: Anticancer activity of cis-dichlorodiammineplatinum (II) and some relevant chemistry. Cancer Treat Rep 63:1433–1438, 1979.PubMedGoogle Scholar
  247. 248.
    Douple EB: Cis-diamminedichloroplatinum (II): effects of a representative metal coordination complex on mammalian cells. Pharmac Ther 25:297–326, 1984.Google Scholar
  248. 249.
    Goldstein RS, Mayor GH: The nephrotoxicity of cisplatin. Life Sci 32:685–690, 1983.PubMedGoogle Scholar
  249. 250.
    Makita T, Itagaki S, Ohokawa T: X-ray micro-analysis and ultrastructural localization of cispla-tin in liver and kidney of the rat. Jpn J Cancer Res 76:895–901, 1985.PubMedGoogle Scholar
  250. 251.
    Makita T, Hakoi K, Ohokawa T: X-ray microanalysis and electron microscopy of platinum complex in the epithelium of proximal renal tubules of the cisplatin administered rabbits. Cell Biol Internat Rep 10:447–454, 1986.Google Scholar
  251. 252.
    Gordon JA, Gattone VH: Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991–F998, 1986.Google Scholar
  252. 253.
    Tkacova E, Kuzela S: Interaction of cis-diamminedichloroplatinum (II) with mitochondrial phosphate carrier. Neoplasma 32:679–683, 1985.PubMedGoogle Scholar
  253. 254.
    Weiner MW, Jacobs C: Mechanism of cisplatin nephrotoxicity. Feder Proc 42:2974–2978, 1983.Google Scholar
  254. 255.
    Levi J, Jacobs C, Kaiman SM, et al: Mechanism of cis-platinum nephrotoxicity: I. Effects of sulf-hydryl groups in rat kidneys. J Pharmacol Exp Therap 213:545–550, 1980.Google Scholar
  255. 256.
    Litterst CL, Tong S, Hirokata Y, et al: Alterations in hepatic and renal levels of glutathione and activities of glutathione S-transferases from rats treated with cis-dichlorodiammineplatinum-II. Cancer Chemother Pharmacol 8:67–71, 1982.PubMedGoogle Scholar
  256. 257.
    Leyland-Jones B, Morrow C, Tate S, et al: Cis-diamminedichloroplatinum (II) nephrotoxicity and its relationship to renal gamma-glutamyl transpeptidase and glutathione. Cancer Res 43:6072–6076, 1983.PubMedGoogle Scholar
  257. 258.
    Aull JL, Allen RL, Bapat AR, et al: The effects of platinum complexes on seven enzymes. Biochim Biophys Acta 571:352–358, 1979.PubMedGoogle Scholar
  258. 259.
    Nechay BR, Neldon SL: Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Rep 68:1135–1141, 1984.PubMedGoogle Scholar
  259. 260.
    Neuwelt EA, Glasberg M, Frenkel E, et al: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathologic studies. Ann Neurol 14:316–324, 1983.PubMedGoogle Scholar
  260. 261.
    Glover D, Glick JH, Weiler C, et al: Phase I/II trials of Wr-2721 and cis-platinum. Int J Rad Oncol Biol Phys 12:1509–1512, 1986.Google Scholar
  261. 262.
    Jordan SW, Yuhas JM, Glick JS: Modulation of cis-platinum renal toxicity by the radioprotective agent WR 2721. Exp Molec Pathol 36:297–305, 1982.Google Scholar
  262. 263.
    Pfeifle CE, Howell SB, Felthouse RH, et al: Highdose cisplatin with sodium thiosulfate protection. J Clin Oncol 3:237–244, 1985.PubMedGoogle Scholar
  263. 264.
    Howell SB, Pfeifle CL, Wung WE, et al: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Int Med 97:845–851, 1982.PubMedGoogle Scholar
  264. 265.
    Jones MM, Basinger MA, Mitchell WM, et al: Inhibition of cis-diamminedichloroplatinum (II)-induced renal toxicity in the rat. Cancer Chemother Pharmacol 17:38–42, 1986.PubMedGoogle Scholar
  265. 266.
    Dobyan DC, Bull JM, Strebel FR, et al: Protective effects of o-(b-hydroxyethyl)-rutoside on cis-platinum-induced acute renal failure in the rat. Lab Invest 55:557–563, 1986.PubMedGoogle Scholar
  266. 267.
    Antonovych TT: Gold nephropathy. Ann Clin Lab Sci 11:386–391, 1981.PubMedGoogle Scholar
  267. 268.
    Sigler JW: Parenteral gold in the treatment of rheumatoid arthritis. Am J Med suppl 6:59–62, 1983.Google Scholar
  268. 269.
    Sutton BM: Overview and current status of gold-containing antiarthritic drugs. In: Platinum, Gold, and Other Metal Chemotherapeutic AgentsChemistry and Biochemistry. Lippard SJ (ed) American Chemical Society, Washington, D.C., 1983, pp. 355–369.Google Scholar
  269. 270.
    Lescher FG: Nervous complications following treatment by gold salts. Brit Med J 2:1303–1305, 1936.PubMedGoogle Scholar
  270. 271.
    Forman L, McNair D: Neuritic symptoms following injection of gold salts. Brit Med J 2:116, 1937.Google Scholar
  271. 272.
    Hartfall SJ, Garland HG, Goldie W: Gold treatment of arthritis. Lancet 2:838–842, 1937.Google Scholar
  272. 273.
    Leiper EJR: A case of polyneuritis due to gold. Brit Med J 2:119–120, 1946.Google Scholar
  273. 274.
    Doyle JB, Cannon EF: Severe polyneuritis following gold therapy for rheumatoid arthritis. Ann Int Med 33:1468–1472, 1950.PubMedGoogle Scholar
  274. 275.
    Walsh JC: Gold neuropathy. Neurol 20:455–458, 1970.Google Scholar
  275. 276.
    Katrak M, Pollock M, O’Brien CP, et al: Clinical and morphological features of gold neuropathy. Brain 103:671–693, 1980.PubMedGoogle Scholar
  276. 277.
    Weiss JJ, Thompson GR, Lazaro R: Gold toxicity presenting as peripheral neuropathy. Clin Rheumatol 1:285–289, 1982.PubMedGoogle Scholar
  277. 278.
    Schlumpf U, Meyer M, Ulrich J, et al: Neurologic complications induced by gold treatment. Arth Rheum 26:825–831, 1983.Google Scholar
  278. 279.
    Fam AG, Gordon DA, Sarkozi J, et al: Neurologic complications associated with gold therapy for rheumatoid arthritis. J Rheumatol 11:700–706, 1984.PubMedGoogle Scholar
  279. 280.
    Nicholson D, Scalettar R, Jacobs RP: Rheumatoid rigor: gold induced myokymia. A report and review of the literature. J Rheumatol 13:195–196, 1986.PubMedGoogle Scholar
  280. 281.
    Dick DJ, Raman D: The Guillain Barre syndrome following gold therapy. Scan J Rheumatol 11:119–120, 1982.Google Scholar
  281. 282.
    Furst DE, Levine S, Srinivasan R, et al: A doubleblind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arth Rheum 20:1473–1480, 1977.Google Scholar
  282. 283.
    McAuley DLF, Lecky BRF, Earl CJ: Gold encephalopathy. J Neurol Neurosurg Psych 40:1021–1022, 1977.Google Scholar
  283. 284.
    Dyck PJ, Conn DT, Okazaki H: Necrotizing angiopathic neuropathy: three-dimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin Proc 47:461–475, 1972.PubMedGoogle Scholar
  284. 285.
    Strunk SW, Ziff M: Ultrastructural studies of the passage of gold thiomalate across the renal glomerular capillary wall. Arth Rheum 13:39–52, 1970.Google Scholar
  285. 286.
    Silverberg DS, Kidd EG, Shnitka TK, et al: Gold nephropathy: a clinical and pathologic study. Arth Rheum 13:812–825, 1970.Google Scholar
  286. 287.
    Watanabe I, Whittier FC, Moore J, et al: Gold nephropathy: ultrastructural, fluorescence, and microanalytic studies of two patients. Arch Pathol Lab Med 100:632–635, 1976.PubMedGoogle Scholar
  287. 288.
    Viol GW, Minielly JA, Bistricki T: Gold nephropathy: tissue analysis by x-ray fluorescent spectroscopy. Arch Pathol Lab Med 101:635–640, 1977.PubMedGoogle Scholar
  288. 289.
    Levine JD, Goldstine J, Mayes M, et al: The neurotoxic effect of gold sodium thiomalate on the peripheral nerves of the rat. Arth Rheum 29:897–901, 1986.Google Scholar
  289. 290.
    Brown DH, Smith WE: Gold thiolate complexes in vitro and in vivo. In: Platinum, Gold, and Other Metal Chemotherapeutic Agents: Chemistry and Biochemistry. Lippard SJ (ed). Washington, D.C., American Chemical Society, 1983, pp. 401–418.Google Scholar
  290. 291.
    Crooke ST, Snyder RM, Butt TR, et al: Cellular and molecular pharmacology of auranofin and related gold complexes. Biochem Pharmacol 35:3423–3431, 1986.PubMedGoogle Scholar
  291. 292.
    Persellin RH, Ziff M: The effect of gold salt on lysosomal enzymes of the peritoneal macrophage. Arth Rheum 9:57–65, 1966.Google Scholar
  292. 293.
    Baker MA, Tappel AL: Effects of ligands on gold inhibition of selenium glutathione peroxidase. Biochem Pharmacol 35:2417–2422, 1986.PubMedGoogle Scholar
  293. 294.
    Ganote CE, Beaver DL, Moses HL: Renal gold inclusions. Arch Path 81:429–438, 1966.PubMedGoogle Scholar
  294. 295.
    Windebank AJ: Specific inhibition of myelination by lead in vitro; comparison with arsenic, thallium and mercury. Exp Neurol 94:203–212, 1986.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Karen S. Blisard

There are no affiliations available

Personalised recommendations